Treating hepatitis C virus in HIV patients: are side effects a real obstacle?
Hepatitis C virus-related long-term complications are nowadays a leading cause of morbidity and mortality in HIV-infected persons. According to international guidelines, all HIV/HCV-coinfected patients should be evaluated and, if eligible, treated with pegylated interferon plus ribavirin. The management of anti-HCV treatment side effects, which may be even more serious in HIV patients, is very important to minimize treatment early discontinuations. The purpose of this review is to supply clinicians with an update, provided by the most recent and relevant literature, of underlying mechanisms, incidence, and advice about the management of pegylated interferon and ribavirin side effects in HCV/HIV-coinfected patients.
Gatti
Francesca
F
Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy. francesca_gatti1@virgilio.it
Nasta
Paola
P
Matti
Alessandro
A
Manno
Daniela
D
Mendeni
Monia
M
Puoti
Massimo
M
Carosi
Giampiero
G
D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use
D012254:Ribavirin; D007372:Interferons